Login to Your Account

Denosumbab May Hold Key For an Amgen Recovery?

By Trista Morrison

Monday, February 4, 2008
Although still trading near its 52-week low, Amgen Inc. got a boost at the end of January thanks to better than expected earnings and new data showing that osteoporosis drug denosumab outperformed Fosamax (alendronate, Merck & Co. Inc.) in a Phase III trial. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription